Pierrepont is focused on the development of a portfolio of treatments specifically targeting genetically defined Primary Mitochondrial Diseases
Why mitochondrial Diseases
Mitochondrial disease as a category has been overlooked by the pharmaceutical industry due to its complexity and multi-system manifestations. Varied disease states that share mitochondrial pathology as a common feature have historically been grouped together despite distinct genetic etiologies, which has created hurdles to the development of effective treatments. Recent advances in molecular diagnostics and deeper understanding of mitochondrial biology have led to a better understanding and characterization of individual disorders, and have created the opportunity to develop targeted therapies for distinct disease states.
Driven by the unmet needs and the advances in research, Pierrepont plans to develop a portfolio of novel clinical stage treatments targeted to specific patient populations with nuclear and mitochondrial DNA mutations.
.jpeg)